Open Access

Current status and perspectives on CAR-T therapy

Ji Woong Kim1,Sukmook Lee1,*
Biopharmaceutical Chemistry Major, School of Applied Chemistry, Kookmin University, 02707 Seoul, Republic of Korea
DOI: 10.52586/5033 Volume 26 Issue 12, pp.1393-1395
Submited: 25 November 2021 Revised: 26 November 2021
Accepted: 26 November 2021 Published: 30 December 2021
*Corresponding Author(s):  
Sukmook Lee
Copyright: © 2021 The author(s). Published by BRI. This is an open access article under the CC BY 4.0 license (

[1] June CH, O’Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018; 359: 1361–1365.

[2] Coscia M. Adoptive immunotherapy with CAR modified T cells in cancer current landscape and future perspectives. Frontiers in Bioscience-Landmark. 2019; 24: 1284–1315.

[3] Mueller KT, Waldron E, Grupp SA, Levine JE, Laetsch TW, Pulsipher MA, et al. Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia. Clinical Cancer Research. 2018; 24: 6175–6184.

[4] Till BG, Jensen MC, Wang J, Chen EY, Wood BL, Greisman HA, et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood. 2008; 112: 2261–2271.

[5] Fry TJ, Shah NN, Orentas RJ, Stetler-Stevenson M, Yuan CM, Ramakrishna S, et al. CD22-targeted CAR T cells induce remission in B-all that is naive or resistant to CD19-targeted CAR immunotherapy. Nature Medicine. 2018; 24: 20–28.

[6] Cohen AD, Garfall AL, Stadtmauer EA, et al. Safety and Efficacy of B-Cell Maturation Antigen (BCMA)-Specific Chimeric Antigen Receptor T Cells (CART-BCMA) with Cyclophosphamide Conditioning for Refractory Multiple Myeloma (MM). Blood. 2017; 130:505.

[7] Ramos CA, Ballard B, Zhang H, Dakhova O, Gee AP, Mei Z, et al. Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes. The Journal of Clinical Investigation. 2017; 127: 3462–3471.

[8] Thistlethwaite FC, Gilham DE, Guest RD, Rothwell DG, Pillai M, Burt DJ, et al. The clinical efficacy of firstgeneration carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient preconditioning-dependent respiratory toxicity. Cancer Immunology, Immunotherapy. 2017; 66: 1425–1436.

[9] Ahmed N, Brawley VS, Hegde M, Robertson C, Ghazi A, Gerken C, et al. Human Epidermal Growth Factor Receptor 2 (her2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of her2-Positive Sarcoma. Journal of Clinical Oncology. 2015; 33: 1688–1696.

[10] Mount CW, Majzner RG, Sundaresh S, Arnold EP, Kadapakkam M, Haile S, et al. Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M+ diffuse midline gliomas. Nature Medicine. 2018; 24: 572–579.

[11] Zhai B, Shi D, Gao H, Qi X, Jiang H, Zhang Y, et al. A phase i study of anti-GPC3 chimeric antigen receptor modified T cells (GPC3 CAR-T) in Chinese patients with refractory or relapsed GPC3+ hepatocellular carcinoma (r/r GPC3+ HCC). Journal of Clinical Oncology. 2017; 35: 3049.

[12] Wang Y, Chen M, Wu Z, Tong C, Dai H, Guo Y, et al. CD133-directed CAR T cells for advanced metastasis malignancies: a phase i trial. Oncoimmunology. 2018; 7: e1440169.

[13] O’Rourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mansfield K, Morrissette JJD, et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Science Translational Medicine. 2017; 9

[14] Brown CE, Badie B, Barish ME, Weng L, Ostberg JR, Chang W, et al. Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma. Clinical Cancer Research. 2015; 21: 4062–4072.

[15] Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer Journal. 2021; 11: 69.

Share and Cite
Ji Woong Kim, Sukmook Lee. Current status and perspectives on CAR-T therapy. Frontiers in Bioscience-Landmark. 2021. 26(12); 1393-1395.